UTRECHT, The Netherlands – Gilde Healthcare Partners today announced an investment in Prosonix Ltd. (Oxford, UK), a leader in the development of high value respiratory therapies enabled by its novel and proprietary particle engineering technology. Alongside Gilde Healthcare Partners, new investors Ventech participated in a UKP 11.4 million financing round. Current backers Entrepreneurs Fund, Quest for Growth and Solon Ventures also participated.
The proceeds of the financing will be used to progress the Company’s emerging proprietary product pipeline of mono and multi-component combination therapies, and through Phase 2 Clinical trials as required. Prosonix patented particle engineering technology provides a unique opportunity to develop novel and generic mono and combination respiratory medicines efficiently in a range of affordable and commercially available Metered Dose and Dry Powder Inhalers.
As part of the financing, Edwin de Graaf from Gilde Healthcare Partners and Karl Nägler from Ventech will join the Prosonix Board of Directors.
Prosonix intends to develop and commercialize a portfolio of fast-to-market mono and novel combination inhalation therapy products targeted at a growing market estimated to be circa $28Bn worldwide. Extensive in-vitro testing already indicates that Prosonix will be able to produce respiratory medication that offers distinct and significant therapeutic advantages to patients compared with currently marketed commercial products, independent of delivery device or presentation.
Founded in early 2006, Prosonix has traditionally commercialized its’ technology via partnering with a range of Originator, Specialty, Device and Generic pharma companies. It is now embedded and key to numerous external DPI, MDI, and Intranasal respiratory development programs.
An acknowledged world leader in the use of ultrasonic particle engineering technologies for the development and manufacture of high value pharmaceutical products, Prosonix proprietary and patented process technologies include Sonocrystallization, DISCUS®, UMAX®, SAXTM, and Particle Rounding. Prosonix robust patent estate includes a range of product, formulation, product-by process, process, and equipment patents, and Prosonix technology has already been demonstrated at commercial scale in cGMP and FDA approved facilities. For more information please visit the website at www.prosonix.co.uk.
About Gilde Healthcare Partners
Netherlands-based Gilde Healthcare Partners is a transatlantic venture and growth capital firm focused on private healthcare technologies and services. It has over €400 million under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €15 million in a single portfolio company. By investing in companies with clear, achievable business models, Gilde has used its financial resources and network to create significant value for both its investors and the entrepreneurs it backs. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.nl.
Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start up Facility.